Response rates differed significantly according to BC subtype (p < 0.001): the majority of luminal BC (9/38, 76%) did not achieve axillary response, whereas TN and HER2-positive BC were less likely to show ARD. This evidence concerns the gene ERBB2 and breast cancer.